Halozyme therapeutics, inc. (HALO)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Operating activities:
Net (loss) income

-72,240

-80,330

62,971

-103,023

-32,231

-68,375

-83,479

-53,552

-19,769

-53,241

-58,360

Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation

34,776

35,696

30,670

25,585

20,838

15,274

9,538

8,349

5,569

4,866

4,526

Depreciation and amortization

4,100

2,400

2,200

2,400

1,677

1,762

1,227

1,079

1,095

1,507

1,443

Non-cash interest expense

-

-

1,761

2,896

1,243

2,025

156

9

0

-

-

Payment-in-kind Interest expense on long-term debt

-

-

-

552

879

0

-

-

-

-

-

Accretion of discounts on marketable securities, net

2,484

1,545

303

-13,184

0

-1,457

-1,116

0

0

-

-

Gain (Loss) on Disposition of Property Plant Equipment

-1,400

-5

-46

-8

-8

-233

0

-7

1

-13

-2

Deferral of unearned revenue

0

3,000

22,759

701

4,379

7,045

9,297

2,962

-17,209

-2,388

11,033

Recognition of deferred revenue

3,996

2,832

6,512

9,304

5,789

5,554

-

-

-

-

-

Lease payments deferred

-459

-7

13

0

441

92

-

-

-

0

-

Operating Lease, Impairment Loss

1,100

0

0

-

-

-

-

-

-

-

-

Recognition of deferred rent

0

0

185

370

276

108

-

-

-

-

-

Gain (Loss) on Extinguishment of Debt

-401

0

0

-

-

-

-

-

-

-

-

Other

-7

-9

-16

0

0

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable, net

29,437

-11,613

6,453

-16,730

23,261

52

-6,606

13,441

-65

-1,915

-3,020

Inventories

6,734

17,480

-9,477

5,134

3,083

236

3,499

2,103

373

-966

718

Prepaid expenses and other assets

19,006

5,695

-2,035

-5,626

15,774

265

-1,959

4,421

4,611

2,147

-1,017

Restricted cash

-

-

-

-

-

-

100

-50

-50

-

-

Accounts payable and accrued expenses

4,638

5,696

15,629

-244

13,866

-816

7,888

-3,263

711

3,437

-2,000

Other liabilities

-

-

-

-

-

-

-48

45

172

-314

-113

Net cash provided by (used in) operating activities

-85,423

-49,500

134,053

-50,383

-37,083

-47,518

-49,339

-64,279

-34,300

-45,385

-40,148

Investing activities:
Purchases of marketable securities

389,759

311,112

398,187

155,412

71,482

88,884

48,947

0

0

-

-

Proceeds from maturities of marketable securities

388,250

318,268

235,805

81,783

79,730

57,301

3,375

0

0

-

-

Purchases of property and equipment

4,040

4,663

1,350

3,137

2,360

1,368

2,297

1,413

828

646

1,461

Net cash (used in) provided by investing activities

-5,549

2,493

-163,732

-76,766

5,888

-32,951

-47,869

-1,413

-828

-646

-1,461

Financing activities:
Proceeds from issuance of common stock, net

0

0

134,874

0

0

107,713

0

81,477

0

59,965

38,174

Proceeds from issuance of long-term debt, net

447,350

0

0

203,006

0

0

19,985

29,661

0

0

-

Repayment of long-term debt

108,082

77,516

15,995

54,250

0

0

-

-

-

-

-

Payments of Debt Issuance Costs

279

0

0

-

-

-

-

-

-

-

-

Payments for Repurchase of Common Stock

199,998

0

0

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement

14,224

13,719

12,776

1,865

13,098

6,788

5,079

1,680

4,748

1,858

1,018

Proceeds from exercise of warrants, net

-

-

-

-

-

-

-

-

-

-

6,165

Net cash provided by financing activities

153,215

-63,797

131,655

150,621

13,098

114,501

25,064

112,818

4,748

61,823

45,357

Net increase (decrease) in cash, cash equivalents and restricted cash

62,243

-110,804

101,976

23,472

-18,097

34,032

-72,144

47,126

-30,380

15,791

3,748

Supplemental disclosure of cash flow information:
Interest Paid, Including Capitalized Interest, Operating and Investing Activities

9,029

16,891

20,295

3,886

3,775

3,460

3,099

19

0

0

-

Income Taxes Paid

188

220

3,015

1,441

0

0

-

-

-

-

-

Supplemental disclosure of non-cash investing and financing activities:
Amounts accrued for purchases of property and equipment

61

542

189

75

473

156

100

154

189

13

143

Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction

68

0

0

-

-

-

-

-

-

-

-

Right-of-use assets obtained in exchange for lease obligation

897

0

0

-

-

-

-

-

-

-

-

Payments for Tenant Improvements

0

1,322

13

-

-

-

-

-

-

-

-

Capitalized property and liability associated with a build-to-suit lease arrangement

-

-

-

-

-

-

1,450

1,450

0

0

-